Trial Profile
DAHANCA 26. A phase II unblinded, randomized study of paclitaxel and capecitabine with or without cetuximab as first line treatment of recurrent or metastatic squamous cell head and neck cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2020
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DAHANCA 26
- 12 Dec 2020 Status changed from recruiting to discontinued.
- 20 Feb 2015 New trial record